← All trials
NCT06696820
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 1, 2024
- Primary completion
- Jun 1, 2027
- Completion date
- Dec 1, 2027
- First posted
- Nov 20, 2024
- Last posted
- Nov 20, 2024
- Enrollment
- 416
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Huazhong University of Science and TechnologyLead sponsor
- People's Hospital Of YichangCollaborator
- Huazhong University of Science and TechnologySponsor investigator
- Huazhong University of Science and TechnologyCollaborator
- Huazhong University of Science and TechnologyCollaborator
- Huazhong University of Science and TechnologyCollaborator
- Huazhong University of Science and TechnologyCollaborator
- Wuhan UniversityCollaborator
- Shiyan Taihe HospitalCollaborator
- Wuhan UniversityCollaborator
- Wuhan UniversityCollaborator
- Fudan UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.